Elacestrant, is an estrogen receptor antagonist used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast lesions. It blocks the growth and spread of diseased cells by inhibiting the activity of estrogen receptors. Elacestrant is suitable for postmenopausal women or adult men, especially those whose disease has progressed after at least one endocrine therapy.

What are the indications and efficacy of Elacestrant(Orserdu)?

Elacestrant is mainly used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast lesions. It blocks the growth and spread of diseased cells by inhibiting the activity of estrogen receptors. The efficacy of Elacestrant has been verified in clinical trials, especially in patients who have failed endocrine therapy and have shown significant anti-lesion activity.

Indications of Elacestrant

Elacestrant is suitable for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast lesions. It is particularly suitable for patients whose disease has progressed after at least one endocrine therapy, providing a new treatment option.

Efficacy of Elacesrant

Elacestrant has shown significant anti-lesion activity in clinical trials, especially in patients who have failed endocrine therapy. It effectively slows the growth and spread of lesions and prolongs patients' progression-free survival by inhibiting the activity of estrogen receptors.

Elacestrant has significant efficacy, but patients need to pay attention to its usage and dosage and possible side effects when using it. We will introduce the usage and dosage of Elacestrant in detail.

What is the dosage of Elacestrant?

The recommended dose of Elacestrant is 345 mg once a day, taken orally with food until disease progression or unacceptable toxicity occurs. Patients should pay attention to the combination with food when taking Elacestrant to reduce possible nausea and vomiting.

Recommended dose of Elacestrant

The recommended dose of Elacestrant is 345 mg once a day, taken orally with food. Taking it with food can reduce adverse reactions such as nausea and vomiting. Patients should take Elacestrant at approximately the same time each day to ensure a stable blood concentration of the drug.

Elacestrant dose adjustment

For patients with moderate hepatic impairment (Child-Pugh B class), it is recommended to reduce the dose of Elacestrant to 258 mg once daily. Patients with severe hepatic impairment (Child-Pugh C class) should avoid using Elacestrant. Patients with mild hepatic impairment (Child-Pugh A class) do not need to adjust the dose.

The dosage of Elacestrant needs to be adjusted according to the patient's specific situation, especially for patients with hepatic impairment. Next, we will introduce the precautions of Elacestrant.

What are the precautions of Elacestrant(Orserdu)?

The use of Elacestrant requires special attention to dyslipidemia and embryo-fetal toxicity. Patients should monitor blood lipids regularly during medication and take effective contraceptive measures to avoid harm to the fetus.

Monitoring of dyslipidemia

Elacestrant may cause hypercholesterolemia and hypertriglyceridemia. Patients should monitor their blood lipids regularly before starting medication and while taking Elacestrant. If dyslipidemia occurs, the doctor may adjust the drug dosage or take other treatment measures.

Prevention of embryo-fetal toxicity

Elacestrant may cause harm to the fetus. Pregnant women and women of reproductive potential should take effective contraceptive measures during the use of Elacestrant. It is recommended to use effective contraceptive methods during treatment and within 1 week after the last dose to avoid harm to the fetus.

Elacestrant is a prescription drug. Patients should strictly follow the doctor's instructions when using it, monitor blood lipids and liver function regularly, and prevent possible serious adverse reactions.